PulseSight Therapeutics is a clinical-stage biotech company developing disruptive, non-viral gene therapies dedicated to ophthalmology, with a current focus on age-related macular degeneration (AMD) including late-stage dry AMD/Geographic atrophy (GA) and wet AMD.
Latest news
October 9, 2026
EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study
October 8, 2026
PulseSight’s PST-611 Shows 35-52% Slowing of Retinal Cell Loss Biomarkers in Phase I Geographic Atrophy Trial
October 7, 2026
New PST-611 Data Suggest Slower GA Progression